{"schema_version":"secwatch.filing_event.v1","accession":"0000875045-23-000027","form_type":"8-K","ticker":"BIIB","cik":"0000875045","company_name":"BIOGEN INC.","filed_at":"2023-07-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.838979+00:00","generated_at":"2026-06-13T03:45:27.970889+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Biogen Q2 revenue $2.46B (-5% YoY); launches LEQEMBI, announces net $700M cost savings by 2025","bullets":["Q2 revenue $2,456M; GAAP EPS $4.07, non-GAAP EPS $4.02; EPS down 44% and 23% YoY respectively.","Launched Alzheimer's drug LEQEMBI in U.S. during Q2.","Fit for Growth program: ~$1B gross savings, ~$300M reinvested, net ~$700M by 2025; ~1,000 headcount reduction.","TECFIDERA EU regulatory protection extended to Feb 2, 2025; new SPINRAZA data in SMA post gene therapy.","Reaffirmed full-year 2023 guidance; R&D pipeline prioritization substantially complete."],"urls":{"canonical":"https://secwatch.observer/filing/0000875045-23-000027","json":"https://secwatch.observer/filing/0000875045-23-000027.json","markdown":"https://secwatch.observer/filing/0000875045-23-000027.md","text":"https://secwatch.observer/filing/0000875045-23-000027.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/875045/000087504523000027/0000875045-23-000027-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/875045/000087504523000027/biib-20230725.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T03:45:27.970889+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ac943a01be2676bc5fbffaef6f9def5d9ce4535c","claim":"BIOGEN INC. reported second quarter 2023 results: revenue $2,456 million, EPS $4.07. Guidance reaffirmed.","evidence_excerpt":"Biogen reports second quarter 2023 results and reaffirms full year 2023 guidance; LEQEMBI launched in the U.S. Second quarter revenue $2,456 million; GAAP diluted EPS $4.07; Non-GAAP diluted EPS $4.02","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/875045/000087504523000027/0000875045-23-000027-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter 2023"},{"label":"Revenue","value":"$2,456 million"},{"label":"EPS","value":"$4.07"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}